Increased ILC3s associated with higher levels of IL-1β aggravates inflammatory arthritis in mice lacking phagocytic NADPH oxidase

Eur J Immunol. 2019 Nov;49(11):2063-2073. doi: 10.1002/eji.201948141. Epub 2019 Aug 6.

Abstract

The role of redox regulation in immune-mediated arthritis has been previously described. However, the relationship between innate immune cells, including innate lymphoid cells (ILCs) and phagocyte-derived ROS, in this process remains unclear. Here, we characterize ILCs and measure the IL-1 family cytokines along with other cytokines relevant to ILC functions and development in serum-induced arthritic joints in wild type and phagocytic NADPH oxidase (NOX2)-deficient Ncf1-/- mice. We found more severe serum-induced joint inflammation and increased NCR+ ILC3s in inflamed joints of Ncf1-/- mice. Furthermore, in vitro stimulation with IL-1β on Tbet+ ILC1s from joints facilitated their differentiation into ROR-γt+ ILC3s. Moreover, treatment with IL-1 antagonists effectively lowered the proportions of NCR+ ILC3s and IL-17A producing ILC3s in Ncf1-/- arthritic mice and ameliorated the joint inflammation. These results suggest that NOX2 is an essential regulator of ILC transdifferentiation and may mediate this process in a redox-dependent manner through IL-1β production in the inflammatory joint. Our findings shed important light on the role of ILCs in the initiation and progression in tissue inflammation and delineate a novel innate immune cell-mediated pathogenic mechanism through which redox regulation may determine the direction of immune responses in joints.

Keywords: NADPH oxidase; chronic granulomatous disease; innate lymphoid cells; reactive oxygen species; serum-induced arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antirheumatic Agents / pharmacology
  • Arthritis, Experimental / chemically induced
  • Arthritis, Experimental / drug therapy
  • Arthritis, Experimental / immunology
  • Arthritis, Experimental / pathology
  • Gene Expression Regulation / immunology
  • Immunity, Innate / drug effects
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin-17 / genetics
  • Interleukin-17 / immunology
  • Interleukin-1beta / genetics
  • Interleukin-1beta / immunology*
  • Lymphocytes / drug effects
  • Lymphocytes / immunology*
  • Lymphocytes / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NADPH Oxidase 2 / deficiency*
  • NADPH Oxidase 2 / genetics
  • NADPH Oxidase 2 / immunology
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / immunology
  • Oxidation-Reduction / drug effects
  • Phagocytes / drug effects
  • Phagocytes / immunology
  • Phagocytes / pathology
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / immunology*
  • Serum / immunology
  • Signal Transduction
  • T-Box Domain Proteins / genetics
  • T-Box Domain Proteins / immunology
  • Tarsus, Animal / drug effects
  • Tarsus, Animal / immunology*
  • Tarsus, Animal / pathology

Substances

  • Antirheumatic Agents
  • IL1B protein, mouse
  • Il17a protein, mouse
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-17
  • Interleukin-1beta
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Reactive Oxygen Species
  • Rorc protein, mouse
  • T-Box Domain Proteins
  • T-box transcription factor TBX21
  • Cybb protein, mouse
  • NADPH Oxidase 2